Systemic Hematologic Status Following Intraventricular Recombinant Tissue-Type Plasminogen Activator for Intraventricular Hemorrhage The CLEAR IVH Study Group

作者：Herrick Daniel B^*; Ziai Wendy C; Thompson Carol B; Lane Karen; McBee Nichol A; Hanley Daniel F

来源：Stroke, 2011, 42(12): 3631-U472.

DOI：10.1161/STROKEAHA.111.625749

• coagulation
• intracerebral hemorrhage
• thrombolysis

Background and Purpose-This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).
Methods-Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.
Results-Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.
Conclusions-Intraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis. Clinical Trial Registration-URL: http://clinicaltrials. gov. Unique identifier: NCT00650858. (Stroke. 2011; 42: 3631-3633.)

• 出版日期2011-12